CN106619149A - Method for preparing nicotinamide-coated multivesicular liposomes - Google Patents
Method for preparing nicotinamide-coated multivesicular liposomes Download PDFInfo
- Publication number
- CN106619149A CN106619149A CN201710050472.1A CN201710050472A CN106619149A CN 106619149 A CN106619149 A CN 106619149A CN 201710050472 A CN201710050472 A CN 201710050472A CN 106619149 A CN106619149 A CN 106619149A
- Authority
- CN
- China
- Prior art keywords
- amino acid
- osmotic pressure
- organic solvent
- pressure regulator
- niacinamide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 title claims abstract description 75
- 235000005152 nicotinamide Nutrition 0.000 title claims abstract description 50
- 239000011570 nicotinamide Substances 0.000 title claims abstract description 50
- 229960003966 nicotinamide Drugs 0.000 title claims abstract description 50
- 239000002502 liposome Substances 0.000 title abstract description 35
- 238000000034 method Methods 0.000 title description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 68
- 150000001413 amino acids Chemical class 0.000 claims abstract description 54
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims abstract description 50
- 239000000839 emulsion Substances 0.000 claims abstract description 44
- 239000003960 organic solvent Substances 0.000 claims abstract description 44
- 230000003204 osmotic effect Effects 0.000 claims abstract description 43
- 230000007935 neutral effect Effects 0.000 claims abstract description 36
- 239000003995 emulsifying agent Substances 0.000 claims abstract description 35
- 239000012071 phase Substances 0.000 claims abstract description 34
- 239000008367 deionised water Substances 0.000 claims abstract description 32
- 229910021641 deionized water Inorganic materials 0.000 claims abstract description 32
- 150000002632 lipids Chemical class 0.000 claims abstract description 32
- 235000012000 cholesterol Nutrition 0.000 claims abstract description 25
- 239000012074 organic phase Substances 0.000 claims abstract description 19
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims abstract description 11
- -1 nicotinamide, amino acid Chemical class 0.000 claims abstract description 11
- 239000000725 suspension Substances 0.000 claims abstract description 7
- 235000001014 amino acid Nutrition 0.000 claims description 57
- 239000000203 mixture Substances 0.000 claims description 39
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 15
- 238000002360 preparation method Methods 0.000 claims description 13
- 239000002994 raw material Substances 0.000 claims description 11
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims description 10
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 claims description 10
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 claims description 8
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 claims description 8
- 229930182478 glucoside Natural products 0.000 claims description 8
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 7
- 238000002156 mixing Methods 0.000 claims description 7
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 6
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims description 6
- 150000008131 glucosides Chemical class 0.000 claims description 6
- 238000003756 stirring Methods 0.000 claims description 6
- RBNPOMFGQQGHHO-UHFFFAOYSA-N -2,3-Dihydroxypropanoic acid Natural products OCC(O)C(O)=O RBNPOMFGQQGHHO-UHFFFAOYSA-N 0.000 claims description 5
- JLPULHDHAOZNQI-ZTIMHPMXSA-N 1-hexadecanoyl-2-(9Z,12Z-octadecadienoyl)-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/C\C=C/CCCCC JLPULHDHAOZNQI-ZTIMHPMXSA-N 0.000 claims description 5
- RBNPOMFGQQGHHO-UWTATZPHSA-N D-glyceric acid Chemical compound OC[C@@H](O)C(O)=O RBNPOMFGQQGHHO-UWTATZPHSA-N 0.000 claims description 5
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 5
- JZNWSCPGTDBMEW-UHFFFAOYSA-N Glycerophosphorylethanolamin Natural products NCCOP(O)(=O)OCC(O)CO JZNWSCPGTDBMEW-UHFFFAOYSA-N 0.000 claims description 5
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 claims description 5
- 229930064664 L-arginine Natural products 0.000 claims description 5
- 235000014852 L-arginine Nutrition 0.000 claims description 5
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims description 5
- 239000004472 Lysine Substances 0.000 claims description 5
- 229930006000 Sucrose Natural products 0.000 claims description 5
- 229930003427 Vitamin E Natural products 0.000 claims description 5
- 229910000147 aluminium phosphate Inorganic materials 0.000 claims description 5
- 229920001400 block copolymer Polymers 0.000 claims description 5
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 claims description 5
- 239000008103 glucose Substances 0.000 claims description 5
- 235000010445 lecithin Nutrition 0.000 claims description 5
- 239000000787 lecithin Substances 0.000 claims description 5
- 229940067606 lecithin Drugs 0.000 claims description 5
- 235000018977 lysine Nutrition 0.000 claims description 5
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 claims description 5
- 150000008104 phosphatidylethanolamines Chemical class 0.000 claims description 5
- 239000002504 physiological saline solution Substances 0.000 claims description 5
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims description 5
- 229920000053 polysorbate 80 Polymers 0.000 claims description 5
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 5
- 229940083466 soybean lecithin Drugs 0.000 claims description 5
- 239000000126 substance Substances 0.000 claims description 5
- 239000005720 sucrose Substances 0.000 claims description 5
- PHYFQTYBJUILEZ-IUPFWZBJSA-N triolein Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC(OC(=O)CCCCCCC\C=C/CCCCCCCC)COC(=O)CCCCCCC\C=C/CCCCCCCC PHYFQTYBJUILEZ-IUPFWZBJSA-N 0.000 claims description 5
- 235000019165 vitamin E Nutrition 0.000 claims description 5
- 229940046009 vitamin E Drugs 0.000 claims description 5
- 239000011709 vitamin E Substances 0.000 claims description 5
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 4
- BTFJIXJJCSYFAL-UHFFFAOYSA-N icosan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCCCO BTFJIXJJCSYFAL-UHFFFAOYSA-N 0.000 claims description 4
- VLPFTAMPNXLGLX-UHFFFAOYSA-N trioctanoin Chemical compound CCCCCCCC(=O)OCC(OC(=O)CCCCCCC)COC(=O)CCCCCCC VLPFTAMPNXLGLX-UHFFFAOYSA-N 0.000 claims description 4
- NOPFSRXAKWQILS-UHFFFAOYSA-N docosan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCCCCCO NOPFSRXAKWQILS-UHFFFAOYSA-N 0.000 claims description 3
- 125000001033 ether group Chemical group 0.000 claims description 3
- 125000002791 glucosyl group Chemical group C1([C@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 claims description 3
- 229910052757 nitrogen Inorganic materials 0.000 claims description 3
- 125000000185 sucrose group Chemical group 0.000 claims description 3
- 229940093609 tricaprylin Drugs 0.000 claims description 3
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 claims description 2
- NRJAVPSFFCBXDT-HUESYALOSA-N 1,2-distearoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC NRJAVPSFFCBXDT-HUESYALOSA-N 0.000 claims description 2
- DKPFZGUDAPQIHT-UHFFFAOYSA-N Butyl acetate Natural products CCCCOC(C)=O DKPFZGUDAPQIHT-UHFFFAOYSA-N 0.000 claims description 2
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 claims description 2
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 claims description 2
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 claims description 2
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 claims description 2
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 claims description 2
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims description 2
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 claims description 2
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 claims description 2
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 claims description 2
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 claims description 2
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 claims description 2
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 claims description 2
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 2
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 claims description 2
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 claims description 2
- 235000004279 alanine Nutrition 0.000 claims description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims description 2
- 229960000735 docosanol Drugs 0.000 claims description 2
- 235000013922 glutamic acid Nutrition 0.000 claims description 2
- 239000004220 glutamic acid Substances 0.000 claims description 2
- 235000011187 glycerol Nutrition 0.000 claims description 2
- 229940074046 glyceryl laurate Drugs 0.000 claims description 2
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims description 2
- 235000004400 serine Nutrition 0.000 claims description 2
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 claims description 2
- 239000004474 valine Substances 0.000 claims description 2
- 238000005253 cladding Methods 0.000 claims 6
- 241000196324 Embryophyta Species 0.000 claims 2
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical class [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 claims 2
- 229940082500 cetostearyl alcohol Drugs 0.000 claims 2
- 239000012530 fluid Substances 0.000 claims 2
- 229920001451 polypropylene glycol Polymers 0.000 claims 2
- 102000004196 processed proteins & peptides Human genes 0.000 claims 2
- OULAJFUGPPVRBK-UHFFFAOYSA-N tetratriacontyl alcohol Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCO OULAJFUGPPVRBK-UHFFFAOYSA-N 0.000 claims 2
- 238000002604 ultrasonography Methods 0.000 claims 2
- UFSKIYBOKFBSOA-MLYSRARTSA-N (2r,3s,4s,5r)-2-(hydroxymethyl)-6-octadecoxyoxane-3,4,5-triol Chemical compound CCCCCCCCCCCCCCCCCCOC1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O UFSKIYBOKFBSOA-MLYSRARTSA-N 0.000 claims 1
- DWNBOPVKNPVNQG-LURJTMIESA-N (2s)-4-hydroxy-2-(propylamino)butanoic acid Chemical compound CCCN[C@H](C(O)=O)CCO DWNBOPVKNPVNQG-LURJTMIESA-N 0.000 claims 1
- DMBUODUULYCPAK-UHFFFAOYSA-N 1,3-bis(docosanoyloxy)propan-2-yl docosanoate Chemical compound CCCCCCCCCCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCCCCCCCCCC DMBUODUULYCPAK-UHFFFAOYSA-N 0.000 claims 1
- 241000283153 Cetacea Species 0.000 claims 1
- 235000010358 acesulfame potassium Nutrition 0.000 claims 1
- 239000002253 acid Substances 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 230000003750 conditioning effect Effects 0.000 claims 1
- 238000001816 cooling Methods 0.000 claims 1
- BIABMEZBCHDPBV-UHFFFAOYSA-N dipalmitoyl phosphatidylglycerol Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(COP(O)(=O)OCC(O)CO)OC(=O)CCCCCCCCCCCCCCC BIABMEZBCHDPBV-UHFFFAOYSA-N 0.000 claims 1
- 150000002148 esters Chemical class 0.000 claims 1
- 239000004519 grease Substances 0.000 claims 1
- CKQVRZJOMJRTOY-UHFFFAOYSA-N octadecanoic acid;propane-1,2,3-triol Chemical compound OCC(O)CO.CCCCCCCCCCCCCCCCCC(O)=O CKQVRZJOMJRTOY-UHFFFAOYSA-N 0.000 claims 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 1
- 150000003904 phospholipids Chemical class 0.000 abstract description 25
- 229910001873 dinitrogen Inorganic materials 0.000 abstract description 5
- 239000000243 solution Substances 0.000 description 28
- DFPAKSUCGFBDDF-ZQBYOMGUSA-N [14c]-nicotinamide Chemical compound N[14C](=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-ZQBYOMGUSA-N 0.000 description 12
- 238000002525 ultrasonication Methods 0.000 description 9
- 238000000265 homogenisation Methods 0.000 description 8
- 239000002537 cosmetic Substances 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 239000002245 particle Substances 0.000 description 5
- 235000003704 aspartic acid Nutrition 0.000 description 4
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 4
- 238000005303 weighing Methods 0.000 description 4
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical class OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 3
- PHYFQTYBJUILEZ-UHFFFAOYSA-N Trioleoylglycerol Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC(OC(=O)CCCCCCCC=CCCCCCCCC)COC(=O)CCCCCCCC=CCCCCCCCC PHYFQTYBJUILEZ-UHFFFAOYSA-N 0.000 description 3
- 239000013543 active substance Substances 0.000 description 3
- 229940081733 cetearyl alcohol Drugs 0.000 description 3
- 239000011248 coating agent Substances 0.000 description 3
- 238000000576 coating method Methods 0.000 description 3
- 230000007794 irritation Effects 0.000 description 3
- 229940100460 peg-100 stearate Drugs 0.000 description 3
- 229920002503 polyoxyethylene-polyoxypropylene Polymers 0.000 description 3
- 239000004094 surface-active agent Substances 0.000 description 3
- 229940117972 triolein Drugs 0.000 description 3
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 230000003020 moisturizing effect Effects 0.000 description 2
- 230000002087 whitening effect Effects 0.000 description 2
- CITHEXJVPOWHKC-UUWRZZSWSA-N 1,2-di-O-myristoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCC CITHEXJVPOWHKC-UUWRZZSWSA-N 0.000 description 1
- KILNVBDSWZSGLL-KXQOOQHDSA-N 1,2-dihexadecanoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCC KILNVBDSWZSGLL-KXQOOQHDSA-N 0.000 description 1
- OKMWKBLSFKFYGZ-UHFFFAOYSA-N 1-behenoylglycerol Chemical compound CCCCCCCCCCCCCCCCCCCCCC(=O)OCC(O)CO OKMWKBLSFKFYGZ-UHFFFAOYSA-N 0.000 description 1
- 208000002874 Acne Vulgaris Diseases 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 206010000496 acne Diseases 0.000 description 1
- 230000003255 anti-acne Effects 0.000 description 1
- 230000003712 anti-aging effect Effects 0.000 description 1
- 230000001153 anti-wrinkle effect Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 230000003796 beauty Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 238000007664 blowing Methods 0.000 description 1
- 238000013329 compounding Methods 0.000 description 1
- 229960003724 dimyristoylphosphatidylcholine Drugs 0.000 description 1
- MWRBNPKJOOWZPW-CLFAGFIQSA-N dioleoyl phosphatidylethanolamine Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC(COP(O)(=O)OCCN)OC(=O)CCCCCCC\C=C/CCCCCCCC MWRBNPKJOOWZPW-CLFAGFIQSA-N 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000004945 emulsification Methods 0.000 description 1
- 238000005265 energy consumption Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 150000002191 fatty alcohols Chemical class 0.000 description 1
- 229940049654 glyceryl behenate Drugs 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 231100000344 non-irritating Toxicity 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 210000002706 plastid Anatomy 0.000 description 1
- 229940051841 polyoxyethylene ether Drugs 0.000 description 1
- 229920000056 polyoxyethylene ether Polymers 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- ARIWANIATODDMH-UHFFFAOYSA-N rac-1-monolauroylglycerol Chemical compound CCCCCCCCCCCC(=O)OCC(O)CO ARIWANIATODDMH-UHFFFAOYSA-N 0.000 description 1
- 230000008591 skin barrier function Effects 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- LADGBHLMCUINGV-UHFFFAOYSA-N tricaprin Chemical compound CCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCC)COC(=O)CCCCCCCCC LADGBHLMCUINGV-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
- A61K8/14—Liposomes; Vesicles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
- A61K8/44—Aminocarboxylic acids or derivatives thereof, e.g. aminocarboxylic acids containing sulfur; Salts; Esters or N-acylated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/55—Phosphorus compounds
- A61K8/553—Phospholipids, e.g. lecithin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/63—Steroids; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/67—Vitamins
- A61K8/673—Vitamin B group
- A61K8/675—Vitamin B3 or vitamin B3 active, e.g. nicotinamide, nicotinic acid, nicotinyl aldehyde
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/10—General cosmetic use
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/41—Particular ingredients further characterized by their size
- A61K2800/412—Microsized, i.e. having sizes between 0.1 and 100 microns
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Birds (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Dermatology (AREA)
- Medicinal Preparation (AREA)
- Cosmetics (AREA)
Abstract
一种包覆烟酰胺的多囊泡脂质体,由磷脂、中性脂质、胆固醇、有机溶剂、亲水性乳化剂、烟酰胺、氨基酸、渗透压调节剂和去离子水组成。本发明将磷脂、胆固醇和中性脂质溶于有机溶剂中,作为有机相;将烟酰胺、氨基酸、渗透压调节剂和去离子水混合均匀作为内水相;均质有机相组分,将内水相组分加入,制得W/O型初乳液;将亲水性乳化剂、氨基酸、渗透压调节剂和去离子水混合,分散作为外水相;均质外水相组分,加入W/O型初乳液组分,均质后进行超声,再搅拌冷却至室温,形成W/O/W型多重乳液;再将多重乳液分散于氨基酸溶液中,通入氮气除去有机溶剂,即得包覆烟酰胺的多囊泡脂质体悬浮液。本发明提高了烟酰胺的稳定性。
A multivesicle liposome coated with nicotinamide is composed of phospholipid, neutral lipid, cholesterol, organic solvent, hydrophilic emulsifier, nicotinamide, amino acid, osmotic pressure regulator and deionized water. In the present invention, phospholipids, cholesterol and neutral lipids are dissolved in an organic solvent as an organic phase; nicotinamide, amino acid, osmotic pressure regulator and deionized water are uniformly mixed as an internal water phase; the homogeneous organic phase components are The inner water phase components are added to prepare W/O type primary emulsion; the hydrophilic emulsifier, amino acid, osmotic pressure regulator and deionized water are mixed and dispersed as the outer water phase; the homogeneous outer water phase components are added The W/O type primary emulsion components are homogenized, ultrasonicated, then stirred and cooled to room temperature to form a W/O/W type multiple emulsion; then the multiple emulsion is dispersed in the amino acid solution, and nitrogen gas is introduced to remove the organic solvent to obtain Suspension of multivesicular liposomes coated with niacinamide. The invention improves the stability of nicotinamide.
Description
技术领域technical field
本发明属于化妆品领域,涉及一种脂质体,具体来说是一种包覆烟酰胺的多囊泡脂质体及其制备方法。The invention belongs to the field of cosmetics and relates to a liposome, in particular to a multivesicle liposome coated with nicotinamide and a preparation method thereof.
背景技术Background technique
烟酰胺是维生素B3的一种衍生物,是一种多功能活性物,近年来越来越为人们所重视,其具有6大护肤功效:美白、抗衰老、改善皮肤屏障功能、保湿、控油与缩小毛孔、治疗痤疮。因此,其在化妆品中的应用涉及到美白产品、祛皱产品、润肤产品、祛痘产品、洗护发产品。但烟酰胺对pH非常敏感,稳定性差,其在pH值高于或低于6的溶液中,会水解形成烟酸,造成皮肤过敏;此外,烟酰胺在潮热的环境下表现出较明显的结块性,储存过程中稳定性差,因此限制了烟酰胺在化妆品中的广泛使用。Niacinamide, a derivative of vitamin B3, is a multifunctional active substance that has attracted more and more attention in recent years. It has 6 major skin care effects: whitening, anti-aging, improving skin barrier function, moisturizing, oil control and Shrink pores, treat acne. Therefore, its application in cosmetics involves whitening products, anti-wrinkle products, moisturizing products, anti-acne products, and hair care products. However, nicotinamide is very sensitive to pH and has poor stability. In a solution with a pH value higher or lower than 6, it will be hydrolyzed to form nicotinic acid, causing skin allergies; Caking and poor stability during storage, thus limiting the widespread use of niacinamide in cosmetics.
多囊脂质体(multivesieularliposomes,MVLs),又称多囊泡脂质体,是一种结构特殊的新型脂质体制剂,其不连续的水性内腔被非同心的类脂以及磷脂膜所分隔,形成许多细微的囊泡。MVLS颗粒呈蜂巢状,粒径大小一般在1-100μm之间。MVLs多囊泡的结构使其具有更多的水溶性物质包封容积,水室体积占颗粒总体积的95%,其水溶性物质的载活性物量比传统的单层脂质体和多层脂质体要高得多;当某个囊泡破裂时,活性物质从破裂囊泡释出,完整的囊泡仍然可以保持原状,因而有很好的缓释效应;脂质层的非同心结构使脂质体的稳定性增加,且活性物的释放时间延长。Multivesicular liposomes (MVLs), also known as multivesicular liposomes, are a new type of liposome preparation with a special structure, and its discontinuous aqueous lumen is separated by non-concentric lipid and phospholipid membranes. , forming many tiny vesicles. MVLS particles are honeycomb-shaped, and the particle size is generally between 1-100 μm. The structure of MVLs multivesicles makes it have more encapsulating volume of water-soluble substances, and the volume of the water chamber accounts for 95% of the total particle volume. The plastid is much higher; when a vesicle ruptures, the active substance is released from the ruptured vesicle, and the intact vesicle can still maintain its original shape, so it has a good slow-release effect; the non-concentric structure of the lipid layer makes The stability of the liposome is increased, and the release time of the active substance is prolonged.
对于亲水性物质的包覆需要借助于多囊泡脂质体,将烟酰胺包覆于内水相,形成一种针对于烟酰胺的包覆载体结构。以提高烟酰胺的稳定性、减小刺激性,进而提高烟酰胺的活性和应用广泛性。For the coating of hydrophilic substances, multivesicular liposomes are needed to coat nicotinamide in the inner water phase to form a coating carrier structure for nicotinamide. To improve the stability of nicotinamide, reduce the irritation, and then improve the activity and wide application of nicotinamide.
目前,关于多囊泡脂质体载体技术的研究已经有很多,多为包覆药物应用于医疗行业,其制备工艺较复杂,但包覆烟酰胺的多囊泡脂质体并将其应用于化妆品中的尚未见公开。At present, there have been many studies on multivesicular liposome carrier technology, most of which are coated drugs used in the medical industry. The preparation process is relatively complicated, but multivesicular liposomes coated with nicotinamide and applied to Cosmetics have not yet been published.
发明内容Contents of the invention
针对现有技术中的上述技术问题,本发明提供了一种包覆烟酰胺的多囊泡脂质体及其制备方法,所述的这种包覆烟酰胺的多囊泡脂质体及其制备方法要解决现有技术中的烟酰胺定性差的技术问题。Aiming at the above-mentioned technical problems in the prior art, the present invention provides a multivesicular liposome coated with nicotinamide and a preparation method thereof, the multivesicular liposome coated with nicotinamide and its preparation method The preparation method should solve the technical problem of poor quality of nicotinamide in the prior art.
本发明提供了一种包覆烟酰胺的多囊泡脂质体,按重量百分比计算,其原料组成及含量如下:The invention provides a multivesicular liposome coated with nicotinamide. The composition and content of the raw materials are as follows:
磷脂 1.0~20.0%;Phospholipids 1.0~20.0%;
中性脂质 1.0~10.0%;Neutral lipid 1.0~10.0%;
胆固醇 1.0~10.0%;Cholesterol 1.0~10.0%;
有机溶剂 5.0~20.0%;Organic solvent 5.0~20.0%;
烟酰胺 0.01~5.0%;Niacinamide 0.01~5.0%;
亲水性乳化剂 0.1~12.0%;Hydrophilic emulsifier 0.1~12.0%;
氨基酸 0.1~1.0%;Amino acid 0.1~1.0%;
渗透压调节剂 2.0~8.0%;Osmotic pressure regulator 2.0~8.0%;
去离子水 余量;Deionized water balance;
所述的磷酸为卵磷脂、氢化卵磷脂、大豆磷脂、磷脂酰乙醇胺、二硬脂酰磷脂酰胆碱、二肉豆蔻酰磷脂酰胆碱、二油酰磷脂酰乙醇胺、或者二棕榈酰磷脂酰甘油中的一种或两种以上所组成的混合物;The phosphoric acid is lecithin, hydrogenated lecithin, soybean lecithin, phosphatidylethanolamine, distearoylphosphatidylcholine, dimyristoylphosphatidylcholine, dioleoylphosphatidylethanolamine, or dipalmitoylphosphatidylcholine One or a mixture of two or more glycerin;
所述的中性脂质为三油酸甘油酯、甘油酸、月桂酸甘油酯、三癸酸甘油酯、三辛酸甘油酯、或者维生素E中的一种或两种以上所组成的混合物;The neutral lipid is glyceryl trioleate, glyceric acid, glyceryl laurate, glyceryl tricaprate, glyceryl tricaprylate, or one or a mixture of two or more of vitamin E;
所述的有机溶剂为乙醚、乙醇、丁醇、或者乙酸乙酯中的一种或两种以上所组成的混合物;The organic solvent is one or a mixture of ether, ethanol, butanol, or ethyl acetate;
所述的亲水性乳化剂为吐温80、聚氧乙烯-聚氧丙烯嵌段共聚物、肽类双分子亲油亲水表活、PEG-100硬脂酸酯、甘油硬脂酸酯、花生醇和山嵛醇和花生醇葡糖苷、鲸蜡硬脂醇和鲸蜡硬脂基葡糖苷、脂肪醇聚氧乙烯醚(21EO)、山嵛酸甘油酯、或者鲸蜡硬脂基葡糖苷中的一种或两种以上所组成的混合物;The hydrophilic emulsifier is Tween 80, polyoxyethylene-polyoxypropylene block copolymer, peptide bimolecular lipophilic and hydrophilic surfactant, PEG-100 stearate, glycerol stearate, One of arachidyl alcohol and behenyl alcohol and arachidyl alcohol glucoside, cetearyl alcohol and cetearyl glucoside, fatty alcohol polyoxyethylene ether (21EO), glyceryl behenate, or cetearyl glucoside A mixture of two or more kinds;
所述的氨基酸为赖氨酸、天门冬氨酸、丝氨酸、L-精氨酸、丙氨酸、门冬氨酸、谷氨酸、甘氨酸、组氨酸、色氨酸、酪氨酸、脯氨酸、亮氨酸、或者缬氨酸中的一种或两种以上的混合物;Described amino acid is lysine, aspartic acid, serine, L-arginine, alanine, aspartic acid, glutamic acid, glycine, histidine, tryptophan, tyrosine, proline One or a mixture of two or more of amino acid, leucine, or valine;
所述的渗透压调节剂为葡萄糖、蔗糖、或者生理盐水中的一种或两种以上的混合物。The osmotic pressure regulator is one or a mixture of glucose, sucrose, or physiological saline.
进一步的,上述的一种包覆烟酰胺的多囊泡脂质体,按重量百分比计算,其原料组成及含量如下:Further, the above-mentioned multivesicular liposome coated with nicotinamide has the following raw material composition and content in terms of weight percentage:
磷脂 1.0%;Phospholipids 1.0%;
中性脂质 1.0%;Neutral Lipid 1.0%;
胆固醇 1.0%;Cholesterol 1.0%;
有机溶剂 5.0%;Organic solvent 5.0%;
烟酰胺 0.01%;Niacinamide 0.01%;
亲水性乳化剂 0.1%;Hydrophilic emulsifier 0.1%;
氨基酸 0.1%;Amino acid 0.1%;
渗透压调节剂 2.0%;Osmotic pressure regulator 2.0%;
去离子水 余量;Deionized water balance;
所述的磷脂为卵磷脂;Described phospholipid is lecithin;
所述的中性油脂为三油酸甘油酯;Described neutral fat is glyceryl trioleate;
所述的有机溶剂为乙醚;Described organic solvent is ether;
所述的亲水性乳化剂为吐温80;Described hydrophilic emulsifier is Tween 80;
所述的氨基酸为赖氨酸;Described amino acid is lysine;
所述的渗透压调节剂为葡萄糖。The osmotic pressure regulator is glucose.
进一步的,上述的一种包覆烟酰胺的多囊泡脂质体,按重量百分比计算,其原料组成及含量如下:Further, the above-mentioned multivesicular liposome coated with nicotinamide has the following raw material composition and content in terms of weight percentage:
磷脂 10.0%;Phospholipids 10.0%;
中性脂质 5.0%;Neutral lipid 5.0%;
胆固醇 5.0%;Cholesterol 5.0%;
有机溶剂 12.5%;Organic solvent 12.5%;
烟酰胺 2.5%;Niacinamide 2.5%;
亲水性乳化剂 6.0%;Hydrophilic emulsifier 6.0%;
氨基酸 0.5%;Amino acid 0.5%;
渗透压调节剂 5.0%;Osmotic pressure regulator 5.0%;
去离子水 余量;Deionized water balance;
所述的磷脂为氢化卵磷脂、或者大豆卵磷脂中的一种或两种组成的混合物;The phospholipid is one or a mixture of hydrogenated lecithin or soybean lecithin;
所述的中性物质为甘油酸;Described neutral substance is glyceric acid;
所述的有机溶剂为乙醇;Described organic solvent is ethanol;
所述的亲水性乳化剂为聚氧乙烯-聚氧丙烯嵌段共聚物、或者PEG-100硬脂酸酯中的一种或两种所组成的混合物;The hydrophilic emulsifier is a polyoxyethylene-polyoxypropylene block copolymer or a mixture of one or two of PEG-100 stearate;
所述的氨基酸为天门冬氨酸;The amino acid is aspartic acid;
所述的渗透压调节剂为蔗糖。The osmotic pressure regulator is sucrose.
进一步的,上述的一种包覆烟酰胺的多囊泡脂质体,按重量百分比计算,其原料组成及含量如下:Further, the above-mentioned multivesicular liposome coated with nicotinamide has the following raw material composition and content in terms of weight percentage:
磷脂 20.0%Phospholipids 20.0%
中性脂质 10.0%;Neutral Lipid 10.0%;
胆固醇 10.0%;Cholesterol 10.0%;
有机溶剂 20.0%;Organic solvent 20.0%;
烟酰胺 5.0%;Niacinamide 5.0%;
亲水性乳化剂 12.0%;Hydrophilic emulsifier 12.0%;
氨基酸 1.0%;Amino acid 1.0%;
渗透压调节剂 8.0%;Osmotic pressure regulator 8.0%;
去离子水 余量;Deionized water balance;
所述的磷酸为磷脂酰乙醇胺;Described phosphoric acid is phosphatidylethanolamine;
所述的中性脂质为三辛酸甘油酯、维生素E中的一种或两种所组成的混合物;The neutral lipid is one or a mixture of tricaprylin and vitamin E;
所述的有机溶剂为丁醇;Described organic solvent is butanol;
所述的亲水性乳化剂为肽类双分子亲油亲水表活、鲸蜡硬脂醇和鲸蜡硬脂基葡糖苷中的一种或两种所组成的混合物;The hydrophilic emulsifier is a mixture of one or two of peptide bimolecular lipophilic and hydrophilic surfactants, cetearyl alcohol and cetearyl glucoside;
所述的氨基酸为L-精氨酸;The amino acid is L-arginine;
所述的渗透压调节剂为生理盐水。The osmotic pressure regulator is physiological saline.
本发明还提供了上述的一种包覆烟酰胺的多囊泡脂质体的制备方法,包括以下步骤:The present invention also provides the above-mentioned preparation method of multivesicular liposomes coated with nicotinamide, comprising the following steps:
1)按重量百分比称取磷脂、中性脂质、胆固醇、有机溶剂、亲水性乳化剂、烟酰胺、氨基酸、渗透压调节剂和去离子水;1) Weighing phospholipids, neutral lipids, cholesterol, organic solvents, hydrophilic emulsifiers, nicotinamide, amino acids, osmotic pressure regulators and deionized water by weight percentage;
2)将磷脂、胆固醇和中性脂质溶于有机溶剂中,作为有机相;2) dissolving phospholipids, cholesterol and neutral lipids in an organic solvent as an organic phase;
3)配置1~100mmol/L的氨基酸溶液,将烟酰胺、30~60%的氨基酸溶液、30~60%的渗透压调节剂和30~60%的去离子水混合,作为内水相;3) Prepare 1~100mmol/L amino acid solution, mix nicotinamide, 30~60% amino acid solution, 30~60% osmotic pressure regulator and 30~60% deionized water as the inner water phase;
4)将步骤3)中所得内水相加入有机相中,以均质速度7200~30000rpm均质有机相组分,同时将内水相组分加入其中,均质1~15min,制得W/O型初乳液;4) Add the internal water phase obtained in step 3) into the organic phase, homogenize the organic phase components at a homogenization speed of 7200-30000rpm, and simultaneously add the internal water phase components, homogenize for 1-15min, and obtain W/ O-type primary emulsion;
5)将亲水性乳化剂、剩余含量的氨基酸溶液、剩余含量的渗透压调节剂和剩余含量的去离子水的混合,作为外水相;5) mixing the hydrophilic emulsifier, the remaining content of the amino acid solution, the remaining content of the osmotic pressure regulator and the remaining content of deionized water as the external water phase;
6)以均质速度7200~30000rpm均质外水相组分,同时将步骤(3)制得的W/O型初乳液组分加入其中,均质1~15min后,选择超声功率20%~30%,超声5秒停止5秒,对乳状液超声1~20min,搅拌至体系均一并自然冷却降至室温,制成W/O/W型多重乳液;6) Homogenize the outer water phase components at a homogenization speed of 7200-30000rpm, and at the same time add the W/O-type primary emulsion components prepared in step (3) to it. After homogenizing for 1-15 minutes, select the ultrasonic power of 20%- 30%, ultrasonication for 5 seconds and stop for 5 seconds, ultrasonication of the emulsion for 1 to 20 minutes, stirring until the system is uniform and cooled down to room temperature naturally to make a W/O/W multiple emulsion;
7)配置与步骤3)中浓度相同的氨基酸溶液,将得到的多重乳液分散于氨基酸溶液中,其中多重乳液与氨基酸溶液的体积比为5:1~1:5,通入氮气除去多重乳液中的有机溶剂,制得包覆烟酰胺的多囊泡脂质体悬浮液。7) Configure the amino acid solution with the same concentration as in step 3), disperse the obtained multiple emulsion in the amino acid solution, wherein the volume ratio of the multiple emulsion to the amino acid solution is 5:1 to 1:5, and pass nitrogen gas to remove the multiple emulsion Organic solvent, prepared multivesicular liposome suspension coated with nicotinamide.
该步骤7)中的氨基酸溶液的作用是影响水溶液的pH,调节油水界面磷脂的表面电荷,提高多囊泡脂质体的静电稳定性,减少多囊泡脂质体在氮吹除去有机溶剂过程中的破乳现象,并不参与多囊泡脂质体的形成过程,因此配方中氨基酸的含量并不包括此部分。The effect of the amino acid solution in this step 7) is to affect the pH of the aqueous solution, regulate the surface charge of the oil-water interface phospholipid, improve the electrostatic stability of the multivesicular liposome, and reduce the removal of the organic solvent process of the multivesicular liposome by nitrogen blowing The demulsification phenomenon in the formula does not participate in the formation process of multivesicular liposomes, so the content of amino acids in the formula does not include this part.
本发明将磷脂、胆固醇和中性脂质溶于有机溶剂中,作为有机相;将烟酰胺、氨基酸、渗透压调节剂和去离子水混合均匀作为内水相;均质有机相组分,将内水相组分加入,制得W/O型初乳液;将亲水性乳化剂、氨基酸、渗透压调节剂和去离子水混合,分散均匀作为外水相;均质外水相组分,加入之前制备的W/O型初乳液组分,均质后进行超声,再搅拌冷却至室温,形成W/O/W型多重乳液;再将多重乳液分散于氨基酸溶液中,通入氮气除去多重乳液中的有机溶剂,即得包覆烟酰胺的多囊泡脂质体悬浮液。In the present invention, phospholipids, cholesterol and neutral lipids are dissolved in an organic solvent as an organic phase; nicotinamide, amino acid, osmotic pressure regulator and deionized water are uniformly mixed as an internal water phase; the homogeneous organic phase components are The inner water phase components are added to prepare the W/O type primary emulsion; the hydrophilic emulsifier, amino acid, osmotic pressure regulator and deionized water are mixed and dispersed evenly as the outer water phase; the homogeneous outer water phase components, Add the previously prepared W/O-type primary emulsion components, homogenize and perform ultrasonication, then stir and cool to room temperature to form a W/O/W-type multiple emulsion; then disperse the multiple emulsions in the amino acid solution, and pass through nitrogen to remove multiple emulsions. The organic solvent in the emulsion obtains the multivesicular liposome suspension coated with nicotinamide.
本发用了适宜的磷脂、中性脂质、胆固醇、有机溶剂、氨基酸、渗透压调节剂和去离子水的复配方案。制备过程中采用两步乳化法,并且进行超声,因此,最终所得的多囊泡脂质体的分散相粒子的粒径较均一,并且其制备工艺简单、能耗低,形成的乳液体系稳定,不仅给烟酰胺提供了合适的载体,提高了烟酰胺的稳定性,降低了其对皮肤的刺激性,对皮肤温和,吸收快, 兼具功能性和美容性。In the present invention, a compounding scheme of suitable phospholipids, neutral lipids, cholesterol, organic solvents, amino acids, osmotic pressure regulators and deionized water is used. Adopt two-step emulsification method in the preparation process, and carry out ultrasonic, therefore, the particle diameter of the dispersed phase particle of the multivesicular liposome of final gained is relatively uniform, and its preparation process is simple, energy consumption is low, and the emulsion system formed is stable, It not only provides a suitable carrier for niacinamide, improves the stability of niacinamide, reduces its irritation to the skin, is mild to the skin, absorbs quickly, and has both functionality and beauty.
本发明和已有技术相比,其技术进步是显著的。本发明为烟酰胺的包覆提供适合的载体,同时提高烟酰胺的稳定性、减小刺激性,进而提高烟酰胺的活性和应用广泛性,开发出具有作用性强、稳定性好、无毒无害不刺激的含烟酰胺活性物的化妆品。Compared with the prior art, the technical progress of the present invention is remarkable. The invention provides a suitable carrier for the coating of nicotinamide, improves the stability of nicotinamide, reduces irritation, further improves the activity and wide application of nicotinamide, and develops a non-toxic and strong action Harmless and non-irritating cosmetics containing niacinamide actives.
附图说明Description of drawings
图1是实施例1所得的包覆烟酰胺的多囊泡脂质体的显微镜照片Fig. 1 is the photomicrograph of the multivesicular liposomes coated with nicotinamide obtained in Example 1
具体实施方式detailed description
下面通过具体实施例并结合附图对本发明进一步阐述,但并不限制本发明。The present invention will be further described below through specific embodiments in conjunction with the accompanying drawings, but the present invention is not limited.
实施例1Example 1
一种包覆烟酰胺的多囊泡脂质体,按重量百分比计算,其原料组成及含量如下:A multivesicular liposome coated with nicotinamide, calculated by weight percentage, its raw material composition and content are as follows:
磷脂 1.0%;Phospholipids 1.0%;
中性脂质 1.0%;Neutral Lipid 1.0%;
胆固醇 1.0%;Cholesterol 1.0%;
有机溶剂 5.0%;Organic solvent 5.0%;
烟酰胺 0.01%;Niacinamide 0.01%;
亲水性乳化剂 0.1%;Hydrophilic emulsifier 0.1%;
氨基酸 0.1%;Amino acid 0.1%;
渗透压调节剂 2.0%;Osmotic pressure regulator 2.0%;
去离子水 余量;Deionized water balance;
所述的磷脂为卵磷脂;Described phospholipid is lecithin;
所述的中性油脂为三油酸甘油酯;Described neutral fat is glyceryl trioleate;
所述的有机溶剂为乙醚;Described organic solvent is ether;
所述的亲水性乳化剂为吐温80;Described hydrophilic emulsifier is Tween 80;
所述的氨基酸为赖氨酸;Described amino acid is lysine;
所述的渗透压调节剂为葡萄糖;The osmotic pressure regulator is glucose;
上述的一种包覆烟酰胺的多囊泡脂质体的制备方法,具体包括如下步骤:The above-mentioned preparation method of multivesicular liposomes coated with nicotinamide specifically comprises the following steps:
1)按重量百分比称取磷脂、中性脂质、胆固醇、有机溶剂、亲水性乳化剂、烟酰胺、氨基酸、渗透压调节剂和去离子水;1) Weighing phospholipids, neutral lipids, cholesterol, organic solvents, hydrophilic emulsifiers, nicotinamide, amino acids, osmotic pressure regulators and deionized water by weight percentage;
2)将磷脂、胆固醇和中性脂质溶于有机溶剂中,作为有机相;2) dissolving phospholipids, cholesterol and neutral lipids in an organic solvent as an organic phase;
3)配置1~100mmol/L的氨基酸溶液,将烟酰胺、30~60%的氨基酸溶液、30~60%的渗透压调节剂和30~60%的去离子水混合,作为内水相;3) Prepare 1~100mmol/L amino acid solution, mix nicotinamide, 30~60% amino acid solution, 30~60% osmotic pressure regulator and 30~60% deionized water as the inner water phase;
4)将步骤3)中所得内水相加入有机相中,以均质速度7200~30000rpm均质有机相组分,同时将内水相组分加入其中,均质1~15min,制得W/O型初乳液;4) Add the internal water phase obtained in step 3) into the organic phase, homogenize the organic phase components at a homogenization speed of 7200-30000rpm, and simultaneously add the internal water phase components, homogenize for 1-15min, and obtain W/ O-type primary emulsion;
5)将亲水性乳化剂、剩余含量的氨基酸溶液、剩余含量的渗透压调节剂和剩余含量的去离子水的混合,作为外水相;5) mixing the hydrophilic emulsifier, the remaining content of the amino acid solution, the remaining content of the osmotic pressure regulator and the remaining content of deionized water as the external water phase;
6)以均质速度7200~30000rpm均质外水相组分,同时将步骤(3)制得的W/O型初乳液组分加入其中,均质1~15min后,选择超声功率20%~30%,超声5秒停止5秒,对乳状液超声1~20min,搅拌至体系均一并自然冷却降至室温,制成W/O/W型多重乳液;6) Homogenize the outer water phase components at a homogenization speed of 7200-30000rpm, and at the same time add the W/O-type primary emulsion components prepared in step (3) to it, after homogenizing for 1-15 minutes, select the ultrasonic power of 20%- 30%, ultrasonication for 5 seconds and stop for 5 seconds, ultrasonication of the emulsion for 1 to 20 minutes, stirring until the system is uniform and cooled down to room temperature naturally to make a W/O/W multiple emulsion;
7)配置与步骤3)中浓度相同的氨基酸溶液,将得到的多重乳液分散于氨基酸溶液中,其中多重乳液与氨基酸溶液的体积比为5:1~1:5,通入氮气除去多重乳液中的有机溶剂,制得包覆烟酰胺的多囊泡脂质体悬浮液。7) Configure the amino acid solution with the same concentration as in step 3), disperse the obtained multiple emulsion in the amino acid solution, wherein the volume ratio of the multiple emulsion to the amino acid solution is 5:1 to 1:5, and pass nitrogen gas to remove the multiple emulsion Organic solvent, prepared multivesicular liposome suspension coated with nicotinamide.
实施例2Example 2
一种包覆烟酰胺的多囊泡脂质体,按重量百分比计算,其原料组成及含量如下:A multivesicular liposome coated with nicotinamide, calculated by weight percentage, its raw material composition and content are as follows:
磷脂 10.0%;Phospholipids 10.0%;
中性脂质 5.0%;Neutral lipid 5.0%;
胆固醇 5.0%;Cholesterol 5.0%;
有机溶剂 12.5%;Organic solvent 12.5%;
烟酰胺 2.5%;Niacinamide 2.5%;
亲水性乳化剂 6.0%;Hydrophilic emulsifier 6.0%;
氨基酸 0.5%;Amino acid 0.5%;
渗透压调节剂 5.0%;Osmotic pressure regulator 5.0%;
去离子水 余量;Deionized water balance;
所述的磷脂为氢化卵磷脂、大豆卵磷脂中的一种或两种组成的混合物;The phospholipid is one or a mixture of hydrogenated lecithin and soybean lecithin;
所述的中性物质为甘油酸;Described neutral substance is glyceric acid;
所述的有机溶剂为乙醇;Described organic solvent is ethanol;
所述的亲水性乳化剂为聚氧乙烯-聚氧丙烯嵌段共聚物、PEG-100硬脂酸酯中的一种或两种所组成的混合物;The hydrophilic emulsifier is one or a mixture of polyoxyethylene-polyoxypropylene block copolymer and PEG-100 stearate;
所述的氨基酸为天门冬氨酸;The amino acid is aspartic acid;
所述的渗透压调节剂为蔗糖;The osmotic pressure regulator is sucrose;
上述的一种包覆烟酰胺的多囊泡脂质体的制备方法,具体包括如下步骤:The above-mentioned preparation method of multivesicular liposomes coated with nicotinamide specifically comprises the following steps:
1)按重量百分比称取磷脂、中性脂质、胆固醇、有机溶剂、亲水性乳化剂、烟酰胺、氨基酸、渗透压调节剂和去离子水;1) Weighing phospholipids, neutral lipids, cholesterol, organic solvents, hydrophilic emulsifiers, nicotinamide, amino acids, osmotic pressure regulators and deionized water by weight percentage;
2)将磷脂、胆固醇和中性脂质溶于有机溶剂中,作为有机相;2) dissolving phospholipids, cholesterol and neutral lipids in an organic solvent as an organic phase;
3)配置1~100mmol/L的氨基酸溶液,将烟酰胺、30~60%的氨基酸溶液、30~60%的渗透压调节剂和30~60%的去离子水混合,作为内水相;3) Prepare 1~100mmol/L amino acid solution, mix nicotinamide, 30~60% amino acid solution, 30~60% osmotic pressure regulator and 30~60% deionized water as the inner water phase;
4)将步骤3)中所得内水相加入有机相中,以均质速度7200~30000rpm均质有机相组分,同时将内水相组分加入其中,均质1~15min,制得W/O型初乳液;4) Add the internal water phase obtained in step 3) into the organic phase, homogenize the organic phase components at a homogenization speed of 7200-30000rpm, and simultaneously add the internal water phase components, homogenize for 1-15min, and obtain W/ O-type primary emulsion;
5)将亲水性乳化剂、剩余含量的氨基酸溶液、剩余含量的渗透压调节剂和剩余含量的去离子水的混合,作为外水相;5) mixing the hydrophilic emulsifier, the remaining content of the amino acid solution, the remaining content of the osmotic pressure regulator and the remaining content of deionized water as the external water phase;
6)以均质速度7200~30000rpm均质外水相组分,同时将步骤(3)制得的W/O型初乳液组分加入其中,均质1~15min后,选择超声功率20%~30%,超声5秒停止5秒,对乳状液超声1~20min,搅拌至体系均一并自然冷却降至室温,制成W/O/W型多重乳液;6) Homogenize the outer water phase components at a homogenization speed of 7200-30000rpm, and at the same time add the W/O-type primary emulsion components prepared in step (3) to it. After homogenizing for 1-15 minutes, select the ultrasonic power of 20%- 30%, ultrasonication for 5 seconds and stop for 5 seconds, ultrasonication of the emulsion for 1 to 20 minutes, stirring until the system is uniform and cooled down to room temperature naturally to make a W/O/W multiple emulsion;
7)配置与步骤3)中浓度相同的氨基酸溶液,将得到的多重乳液分散于氨基酸溶液中,其中多重乳液与氨基酸溶液的体积比为5:1~1:5,通入氮气除去多重乳液中的有机溶剂,制得包覆烟酰胺的多囊泡脂质体悬浮液。7) Configure the amino acid solution with the same concentration as in step 3), disperse the obtained multiple emulsion in the amino acid solution, wherein the volume ratio of the multiple emulsion to the amino acid solution is 5:1 to 1:5, and pass nitrogen gas to remove the multiple emulsion Organic solvent, prepared multivesicular liposome suspension coated with nicotinamide.
实施例3Example 3
一种包覆烟酰胺的多囊泡脂质体,按重量百分比计算,其原料组成及含量如下:A multivesicular liposome coated with nicotinamide, calculated by weight percentage, its raw material composition and content are as follows:
磷脂 20.0%;Phospholipids 20.0%;
中性脂质 10.0%;Neutral Lipid 10.0%;
胆固醇 10.0%;Cholesterol 10.0%;
有机溶剂 20.0%;Organic solvent 20.0%;
烟酰胺 5.0%;Niacinamide 5.0%;
亲水性乳化剂 12.0%;Hydrophilic emulsifier 12.0%;
氨基酸 1.0%;Amino acid 1.0%;
渗透压调节剂 8.0%;Osmotic pressure regulator 8.0%;
去离子水 14.0%;Deionized water 14.0%;
所述的磷酸为磷脂酰乙醇胺;Described phosphoric acid is phosphatidylethanolamine;
所述的中性脂质为三辛酸甘油酯、维生素E中的一种或两种所组成的混合物;The neutral lipid is one or a mixture of tricaprylin and vitamin E;
所述的有机溶剂为丁醇;Described organic solvent is butanol;
所述的亲水性乳化剂为肽类双分子亲油亲水表活、鲸蜡硬脂醇和鲸蜡硬脂基葡糖苷中的一种或两种组成的混合物;The hydrophilic emulsifier is one or a mixture of peptide bimolecular lipophilic and hydrophilic surfactants, cetearyl alcohol and cetearyl glucoside;
所述的氨基酸为L-精氨酸;The amino acid is L-arginine;
所述的渗透压调节剂为生理盐水;Described osmotic pressure regulator is physiological saline;
上述的一种包覆烟酰胺的多囊泡脂质体的制备方法,具体包括如下步骤:The above-mentioned preparation method of multivesicular liposomes coated with nicotinamide specifically comprises the following steps:
1)按重量百分比称取磷脂、中性脂质、胆固醇、有机溶剂、亲水性乳化剂、烟酰胺、氨基酸、渗透压调节剂和去离子水;1) Weighing phospholipids, neutral lipids, cholesterol, organic solvents, hydrophilic emulsifiers, nicotinamide, amino acids, osmotic pressure regulators and deionized water by weight percentage;
2)将磷脂、胆固醇和中性脂质溶于有机溶剂中,作为有机相;2) dissolving phospholipids, cholesterol and neutral lipids in an organic solvent as an organic phase;
3)配置1~100mmol/L的氨基酸溶液,将烟酰胺、30~60%的氨基酸溶液、30~60%的渗透压调节剂和30~60%的去离子水混合,作为内水相;3) Prepare 1~100mmol/L amino acid solution, mix nicotinamide, 30~60% amino acid solution, 30~60% osmotic pressure regulator and 30~60% deionized water as the inner water phase;
4)将步骤3)中所得内水相加入有机相中,以均质速度7200~30000rpm均质有机相组分,同时将内水相组分加入其中,均质1~15min,制得W/O型初乳液;4) Add the internal water phase obtained in step 3) into the organic phase, homogenize the organic phase components at a homogenization speed of 7200-30000rpm, and simultaneously add the internal water phase components, homogenize for 1-15min, and obtain W/ O-type primary emulsion;
5)将亲水性乳化剂、剩余含量的氨基酸溶液、剩余含量的渗透压调节剂和剩余含量的去离子水的混合,作为外水相;5) mixing the hydrophilic emulsifier, the remaining content of the amino acid solution, the remaining content of the osmotic pressure regulator and the remaining content of deionized water as the external water phase;
6)以均质速度7200~30000rpm均质外水相组分,同时将步骤(3)制得的W/O型初乳液组分加入其中,均质1~15min后,选择超声功率20%~30%,超声5秒停止5秒,对乳状液超声1~20min,搅拌至体系均一并自然冷却降至室温,制成W/O/W型多重乳液;6) Homogenize the outer water phase components at a homogenization speed of 7200-30000rpm, and at the same time add the W/O-type primary emulsion components prepared in step (3) to it. After homogenizing for 1-15 minutes, select the ultrasonic power of 20%- 30%, ultrasonication for 5 seconds and stop for 5 seconds, ultrasonication of the emulsion for 1 to 20 minutes, stirring until the system is uniform and cooled down to room temperature naturally to make a W/O/W multiple emulsion;
7)配置与步骤3)中浓度相同的氨基酸溶液,将得到的多重乳液分散于氨基酸溶液中,其中多重乳液与氨基酸溶液的体积比为5:1~1:5,通入氮气除去多重乳液中的有机溶剂,制得包覆烟酰胺的多囊泡脂质体悬浮液。7) Configure the amino acid solution with the same concentration as in step 3), disperse the obtained multiple emulsion in the amino acid solution, wherein the volume ratio of the multiple emulsion to the amino acid solution is 5:1 to 1:5, and pass nitrogen gas to remove the multiple emulsion Organic solvent, prepared multivesicular liposome suspension coated with nicotinamide.
上述内容仅为本发明构思下的基本说明,而依据本发明的技术方案所作的任何等效变换,均应属于本发明的保护范围。The above content is only a basic description of the concept of the present invention, and any equivalent transformation made according to the technical solution of the present invention shall belong to the protection scope of the present invention.
Claims (5)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710050472.1A CN106619149A (en) | 2017-01-23 | 2017-01-23 | Method for preparing nicotinamide-coated multivesicular liposomes |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710050472.1A CN106619149A (en) | 2017-01-23 | 2017-01-23 | Method for preparing nicotinamide-coated multivesicular liposomes |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN106619149A true CN106619149A (en) | 2017-05-10 |
Family
ID=58842135
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201710050472.1A Pending CN106619149A (en) | 2017-01-23 | 2017-01-23 | Method for preparing nicotinamide-coated multivesicular liposomes |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN106619149A (en) |
Cited By (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107308454A (en) * | 2017-06-21 | 2017-11-03 | 广州市禾基生物科技有限公司 | Liposome and its preparation method and application |
| CN109106657A (en) * | 2018-11-08 | 2019-01-01 | 妃瑶生物科技(上海)有限公司 | A kind of prinsepia utilis royle oil liposome and preparation method thereof |
| CN110812254A (en) * | 2019-07-08 | 2020-02-21 | 圣菲之美(湖北)生物科技有限公司 | Phospholipase-coated multivesicular liposome and preparation method and application thereof |
| CN113827498A (en) * | 2020-06-24 | 2021-12-24 | 南京理工大学 | Preparation method of nicotinamide liposome |
| CN113876642A (en) * | 2021-11-12 | 2022-01-04 | 湖北省麦诗特生物科技有限公司 | Cream composition containing lipid nanoparticles with moisturizing and hydrating effects and preparation method thereof |
| CN114514012A (en) * | 2019-10-15 | 2022-05-17 | 株式会社高丝 | External preparation for skin |
| US11617706B2 (en) | 2020-06-29 | 2023-04-04 | The Procter & Gamble Company | Hair conditioning composition free of fatty alcohol |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1875916A (en) * | 2006-04-27 | 2006-12-13 | 广州市采诗化妆品有限公司 | A whitening moisturizing composition |
| CN101780039A (en) * | 2010-03-05 | 2010-07-21 | 南京海陵中药制药工艺技术研究有限公司 | Tramadol multivesicular liposome and preparation method thereof |
| CN102274183A (en) * | 2010-06-13 | 2011-12-14 | 上海现代药物制剂工程研究中心有限公司 | Preparation method and application of multi-vesicular liposome |
| CN103432009A (en) * | 2013-09-12 | 2013-12-11 | 广东轻工职业技术学院 | Whitening agent liposome coating micro-capsule composition as well as preparation method and application thereof |
| CN103932909A (en) * | 2014-04-25 | 2014-07-23 | 北京博辉瑞进生物科技有限公司 | Composition for facial care and preparation method of composition |
| CN105534905A (en) * | 2015-12-28 | 2016-05-04 | 正大天晴药业集团股份有限公司 | Multi-vesicular liposome containing entecavir and preparation method of multi-vesicular liposome |
-
2017
- 2017-01-23 CN CN201710050472.1A patent/CN106619149A/en active Pending
Patent Citations (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1875916A (en) * | 2006-04-27 | 2006-12-13 | 广州市采诗化妆品有限公司 | A whitening moisturizing composition |
| CN101780039A (en) * | 2010-03-05 | 2010-07-21 | 南京海陵中药制药工艺技术研究有限公司 | Tramadol multivesicular liposome and preparation method thereof |
| CN102274183A (en) * | 2010-06-13 | 2011-12-14 | 上海现代药物制剂工程研究中心有限公司 | Preparation method and application of multi-vesicular liposome |
| CN102274183B (en) * | 2010-06-13 | 2013-08-28 | 上海现代药物制剂工程研究中心有限公司 | Preparation method and application of multi-vesicular liposome |
| CN103432009A (en) * | 2013-09-12 | 2013-12-11 | 广东轻工职业技术学院 | Whitening agent liposome coating micro-capsule composition as well as preparation method and application thereof |
| CN103932909A (en) * | 2014-04-25 | 2014-07-23 | 北京博辉瑞进生物科技有限公司 | Composition for facial care and preparation method of composition |
| CN105534905A (en) * | 2015-12-28 | 2016-05-04 | 正大天晴药业集团股份有限公司 | Multi-vesicular liposome containing entecavir and preparation method of multi-vesicular liposome |
| CN105534905B (en) * | 2015-12-28 | 2017-03-15 | 正大天晴药业集团股份有限公司 | A kind of multivesicular liposome containing Entecavir and preparation method thereof |
Cited By (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107308454A (en) * | 2017-06-21 | 2017-11-03 | 广州市禾基生物科技有限公司 | Liposome and its preparation method and application |
| CN109106657A (en) * | 2018-11-08 | 2019-01-01 | 妃瑶生物科技(上海)有限公司 | A kind of prinsepia utilis royle oil liposome and preparation method thereof |
| CN110812254A (en) * | 2019-07-08 | 2020-02-21 | 圣菲之美(湖北)生物科技有限公司 | Phospholipase-coated multivesicular liposome and preparation method and application thereof |
| CN114514012A (en) * | 2019-10-15 | 2022-05-17 | 株式会社高丝 | External preparation for skin |
| CN113827498A (en) * | 2020-06-24 | 2021-12-24 | 南京理工大学 | Preparation method of nicotinamide liposome |
| US11617706B2 (en) | 2020-06-29 | 2023-04-04 | The Procter & Gamble Company | Hair conditioning composition free of fatty alcohol |
| US11969490B2 (en) | 2020-06-29 | 2024-04-30 | The Procter & Gamble Company | Hair conditioning composition with antimicrobial system |
| CN113876642A (en) * | 2021-11-12 | 2022-01-04 | 湖北省麦诗特生物科技有限公司 | Cream composition containing lipid nanoparticles with moisturizing and hydrating effects and preparation method thereof |
| CN113876642B (en) * | 2021-11-12 | 2023-10-20 | 湖北省麦诗特生物科技有限公司 | A facial cream composition containing lipid nanoparticle with moisturizing effect and its preparation method |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN106619149A (en) | Method for preparing nicotinamide-coated multivesicular liposomes | |
| Kim et al. | Transdermal delivery systems in cosmetics | |
| JP4758915B2 (en) | Multilamellar liposome and production method thereof | |
| CN106726640A (en) | Ascorbic many vesicles of one kind cladding and preparation method thereof | |
| JP3411570B2 (en) | Blended lipid vesicles | |
| Gupta et al. | Glycerosomes: Advanced Liposomal Drug Delivery System. | |
| JP2003327526A (en) | Liposome increased with percentage of enclosed compound | |
| CN113116824A (en) | Nano liposome and preparation method and application thereof | |
| WO2009142018A1 (en) | Method for producing vesicle, vesicle obtained by the production method, and w/o/w emulsion for producing vesicle | |
| CN106726643A (en) | A kind of many vesicles for coating water-soluble glabridin and preparation method thereof | |
| WO2010104128A1 (en) | Ph-responsive liposome | |
| KR100823345B1 (en) | Silica Carrying Nano-Sized Liposomal Emulsion Containing Coenzyme Kyuten and Method for Preparing the Same | |
| CN106726641A (en) | A kind of many vesicles of cladding D panthenols and preparation method thereof | |
| CN105213207B (en) | A kind of non-phospholipid surfactants multiplet liposome and preparation method thereof | |
| EP0521562A1 (en) | Vesicles in non-polar media | |
| JP2016084340A (en) | Skin external preparation and skin barrier function improving agent | |
| CN106726642A (en) | A kind of preparation method of many vesicles for coating OPC | |
| JPH07112969B2 (en) | Alcohol-containing aqueous gel phospholipid composition, method for producing liposome solution for diluting the phospholipid composition, and topical preparation containing the phospholipid composition | |
| JP7740933B2 (en) | Liposome-containing composition for cosmetics, and cosmetics | |
| JP4842553B2 (en) | Method for stabilizing nano-emulsified particles using hydroxycarboxylic acid ester and external preparation for skin containing nano-emulsified particles | |
| AU2019291580B2 (en) | Process for formation of emulsion containing liquid crystal structure | |
| KR19990058599A (en) | Cosmetic composition containing a double capsule | |
| CN110652460B (en) | Compositions containing linoleic acid | |
| CN116785182B (en) | Vesicle for wrapping active substances, preparation method and application thereof | |
| RU2806276C2 (en) | Method of production of emulsion with a liquid crystal structure |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20170510 |
|
| WD01 | Invention patent application deemed withdrawn after publication |